---
figid: PMC6696851__10.1177_2040622319869116-fig8
figtitle: Schematic diagram depicting possible mechanisms involved in the anti-fibrotic
  effect of melatonin and PAA
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6696851
filename: 10.1177_2040622319869116-fig8.jpg
figlink: /pmc/articles/PMC6696851/figure/fig8-2040622319869116/
number: F8
caption: Schematic diagram depicting possible mechanisms involved in the anti-fibrotic
  effect of melatonin and PAA. Renal IRI activated TGF-β signaling and caused renal
  fibrosis. Treatment with both melatonin and PAA simultaneously inhibit renal fibrosis,
  but the underlying mechanisms are totally different. Melatonin treatment targets
  multiple downstream mediators of TGF-β signaling, including Smad2, Smad3, Smad4,
  Smad7, PI3K, ERK1/2, and p38, while PAA treatment attenuates renal fibrosis by selectively
  inhibiting Smad3 phosphorylation via disturbing the interactions of Smad3 with TGFβRI
  and SARA. Interestingly, PAA treatment can enhance the inhibitory effects of melatonin
  on Smad2 and Smad3 phosphorylation. Besides, PAA has greater inhibitory effects
  than melatonin on the activation of Wnt/β-catenin signaling and downstream target
  genes.IRI, ischemia-reperfusion injury; PAA, poricoic acid A; PAI-1, plasminogen
  activator inhibitor-1; SARA, Smad anchor for receptor activation; TGF-β, transforming
  growth factor-β, TGFβRI, transforming growth factor-β receptor II.
papertitle: Combined melatonin and poricoic acid A inhibits renal fibrosis through
  modulating the interaction of Smad3 and β-catenin pathway in AKI-to-CKD continuum.
reftext: Dan-Qian Chen, et al. Ther Adv Chronic Dis. 2019;10:2040622319869116.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9657708
figid_alias: PMC6696851__F8
figtype: Figure
redirect_from: /figures/PMC6696851__F8
ndex: 092cf19f-ded2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6696851__10.1177_2040622319869116-fig8.html
  '@type': Dataset
  description: Schematic diagram depicting possible mechanisms involved in the anti-fibrotic
    effect of melatonin and PAA. Renal IRI activated TGF-β signaling and caused renal
    fibrosis. Treatment with both melatonin and PAA simultaneously inhibit renal fibrosis,
    but the underlying mechanisms are totally different. Melatonin treatment targets
    multiple downstream mediators of TGF-β signaling, including Smad2, Smad3, Smad4,
    Smad7, PI3K, ERK1/2, and p38, while PAA treatment attenuates renal fibrosis by
    selectively inhibiting Smad3 phosphorylation via disturbing the interactions of
    Smad3 with TGFβRI and SARA. Interestingly, PAA treatment can enhance the inhibitory
    effects of melatonin on Smad2 and Smad3 phosphorylation. Besides, PAA has greater
    inhibitory effects than melatonin on the activation of Wnt/β-catenin signaling
    and downstream target genes.IRI, ischemia-reperfusion injury; PAA, poricoic acid
    A; PAI-1, plasminogen activator inhibitor-1; SARA, Smad anchor for receptor activation;
    TGF-β, transforming growth factor-β, TGFβRI, transforming growth factor-β receptor
    II.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFBI
  - WNT1
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - ZFYVE9
  - SAR1A
  - SMAD3
  - SMAD2
  - CTNNB1
  - SMAD7
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD9
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPK3
  - MAPK1
  - CRK
  - MAPK14
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - SNAI1
  - SMN1
  - MMP7
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - SERPINE1
  - RPSA
  - LRP1
  - PTPRA
  - MVP
  - LRP6
  - LRP5
  - MUC1
  - TGFB1
  - Melatonin
  - PAA
  - melatonin
  - Ischemia
---
